Ruthenium Complexes as Anticancer Drugs
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (28 February 2023) | Viewed by 640
Special Issue Editor
Special Issue Information
Dear Colleagues,
Ruthenium complexes of various structural types are among the most studied anticancer metallodrugs. Their structural diversity (e.g., pseudo-octahedral half-sandwich or octahedral tetrachlorido, polypyridyl or cyclometalated complexes) allows chemists to finely tune the physical, chemical and biological properties of Ru complexes, resulting in numerous agents exhibiting high anticancer activity, selectivity towards cancer cells over normal ones, antimetastatic activity, and mechanisms of action different from conventional anticancer chemotherapeutics, such as cisplatin. Importantly, several Ru complexes (NAMI-A, IT-139 (formerly known as NKP-1339) and most recently TLD1433) have entered clinical trials on human oncological patients as promising chemotherapeutics, making Ru one of the most pharmacologically prospective d-block elements for the research and development of new non-platinum anticancer metallodrugs.
This Special Issue aims to uncover some of novel Ru-based anticancer complexes of various structural types, as well as supramolecular drug-delivery systems functionalized by bioactive Ru complexes, and discuss some aspects of the recent advances in this key field of bioorganic, bioorganometallic, and medicinal chemistry. All kinds of contributions (original research papers, reviews, etc.) dealing with anticancer Ru complexes or their supramolecular assemblies (e.g., liposomes or functionalized nanoparticles) are welcome.
Dr. Pavel Štarha
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- coordination complexes
- organometallic chemistry
- bioinorganic chemistry
- bioorganometallic chemistry
- metal-based drugs
- piano-stool complexes
- polypyridyl complexes
- cyclometalated complexes
- drug-delivery systems
- anticancer activity
- mechanism of action
